Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis

touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications.

Questions

1. Could you give us a brief overview of the health burden of Crohn’s disease and colitis? (0:10)
2. What therapies are available to help manage symptoms of Crohn’s and colitis? (1:44)

Disclosures: Gil Melmed discloses consulting for Abbvie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Genetech, Pfizer, Samsung Bioepis, Takeda, Shionogi, Prometheus Labs, Techlab, Fresenius Kabi, and Amgen; and receiving grant/ research support from Pfizer.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

To find out more visit our gastroenterology content here.